- ‘Botulinum resistance lasts for at least 4 years’
- by Jung, Sae-Im Jun 21, 2023 05:52am
Reporter Sae-Im Jung (Reporter Jung): Some say that 'unnecessary proteins can increase immunogenicity, but they do not lead to the formation of neutralizing antibodies.’ Can we say that this opinion lack grounds based on actual clinical
- Policy
- 85% of the public requests more coverage for severe diseases
- by Lee, Jeong-Hwan Jun 21, 2023 05:52am
- A survey found that more than 8 of 10 Koreans are in favor of increasing health insurance spending on new health technologies and new drugs to treat severe diseases such as cancer and rare diseases. Also, over 80% of the respondents agreed that the proportion of new drugs in total health insurance pharmaceutical spending should be increas
- Company
- Camzyos, which prevents sudden cardiac death in young people
- by Jung, Sae-Im Jun 21, 2023 05:51am
- Korea BMS Pharmaceuticals (CEO Lee Hye-young) announced on the 20th that it held a domestic approval meeting for Camzyos, a treatment for 'obstructive hypertrophic cardiomyopathy (oHCM)', on the 19th and introduced its clinical value. Obstructive hypertrophic cardiomyopathy is a severe and rare heart disease in which thickened left ventricular m
- Company
- [two thousandth]Toxins accumulated in Soyul's body every day
- by Jung, Sae-Im Jun 21, 2023 05:50am
- Soyul, who turned 5 this year, stopped growing at 80cm and is no longer growing. Her arms and legs are not straight and straight. If you try to forcefully stretch it, you could break a bone. This is because Soyul's bone density is low enough to be found in an elderly person in his 80s. Soyul also has carpal tunnel syndrome, which affects 7
- Policy
- Mandatory benefit for Erleada impact?
- by Lee, Tak-Sun Jun 20, 2023 05:36am
- As Erleada, a prostate cancer treatment, has received mandatory reimbursement since last April, attention is focusing on whether the co-payment ratio for Xtandi and Zytiga in the same class will be reduced. Currently, Erleada receives mandatory benefits with a co-payment of 5%, and Xtandi·Zytiga receives 30% screening benefits. The Cancer Di
- Policy
- Negotiations between Verquvo and Retevmo begin
- by Lee, Tak-Sun Jun 20, 2023 05:36am
- Retevmo, an anticancer drug with mutations in RET, and Verquvo, a treatment for chronic heart failure, have entered into drug price negotiations with the NHIS. It is said that negotiations are still underway for Cibinqo, which started negotiations on drug prices in March, and Onureg, which started negotiations with the company last month. The
- ‘Risk of resistance to BoNT-A may rise in the next 1-2 yrs'
- by Jung, Sae-Im Jun 20, 2023 05:35am
- Reporter Sae-Im Jung (Reporter Jung): Hello. Welcome to DP Interview. Today’s topic is botulinum toxin, a procedure that men and women both consider an easy option for wrinkles. Due to the popularity of the procedure, awareness of the side effects that can occur from its use, especially resistance, has a
- Policy
- Rationalization of expedited review of new pharmaceuticals
- by Lee, Hye-Kyung Jun 20, 2023 05:35am
- In the case of a new drug developed by a first-in-class pharmaceutical company, a priority review request can be made to the rapid review division of the Ministry of Food and Drug Safety. The Ministry of Food and Drug Safety recently prepared detailed procedures, such as the method of requesting designation from the Minister of Health and Welfar
- Company
- ALS drug Teglutik may be prescribed at general hospitals
- by Eo, Yun-Ho Jun 20, 2023 05:35am
- SK Chemical’s Lou Gehrig's disease treatment ‘Teglutik’ can now be prescribed at general hospitals in Korea. According to industry sources, Teglutik (riluzole) passed the drug committees (DCs) of tertiary hospitals including Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, as well as medical institution
- Company
- SK Biopharmaceuticals’ Cenobamate approved in Canada
- by Chon, Seung-Hyun Jun 19, 2023 06:00am
- SK Biopharmaceuticals announced on the 15th that Cenobamate, a new drug for epilepsy, has received marketing approval from the Canadian Department of Health. Cenobamate's commercialization in Canada is being handled by Paladin Labs, a local pharmaceutical company. Cenobamate is a new drug for epilepsy that SK Biopharmaceuticals is independently
